Penn Medicine Provider
Neurology
Amit Bar-Or, MD, FRCPC
4.9
(64)
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology

About me

  • Director, Center for Neuroinflammation and Neurotherapeutics
  • Chief, Multiple Sclerosis Division
  • Melissa and Paul Anderson President's Distinguished Professor

Education and training

  • Medical School: McGill University
  • Residency: Massachusetts General Hospital
  • Fellowship: Massachusetts General Hospital/Brigham and Women’s Hospital

What my patients think about me

Average Rating
4.9

64 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

March 2025
5.0
5.0
world expert... i mean the guy is definitely a top 10 in his field
March 2025
5.0
5.0
he has good understanding,
February 2025
5.0
5.0
because of their methodical approach to evaluating the underlying causes
February 2025
5.0
5.0
dr bar-or is very thorough and explains all the details about your condition

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Bar-Or is a Penn Medicine physician.

Qualifications and experience

My research

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis , Neurol Neuroimmunol Neuroinflamm, 4(3): 2017


Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; Monophasic demyelination reduces brain growth in children , Neurology: 2017


Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis , N Engl J Med., 376(3): 2017,221-234


Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky J ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , N Engl J., 376(3): 2017,221-234


Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A* Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis , J Immunol., 198(2): 2017,691--698


Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. , Stem Cells Transl Med., pii: sctm.2015-0243(11): 2016


Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore C, Michel L, Althekair F, Rajasekharan S, Gommerman J, Prat A, Fillatreau S and Bar-Or A on behalf of the 'Canadian B cells in MS Team' Proinflammatory GM-CSF producing B cells: implication in multiple sclerosis and B cell depletion therapy , Sci Transl Med, 7(310): 2015,166


Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination , Mult Scler, 22(3): 2016,385-8


Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F Randomized study of teriflunomide effects on immune responses to neo-antigen and recall antigens , Neurol Neuroimmunol Neuroinflamm., 2(2): 2015,e70


Moore CS, Cui QL, Warsi NM, Durafourt BA, Zorko N, Owen DR, Antel JP, and Bar-Or A Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation , J Immunol, 194(2): 2015,761-72


View all publications